GENEART AG will become part of the US-Based Biotechnology Company Life Technologies Corp.

Geneart AG / GENEART AG will become part of the US-Based Biotechnology Company Life Technologies Corp. processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement.

- Life Technologies acquires 58 % of GENEART shares via it´s German subsidiary
Applied Biosystems Deutschland GmbH
- Public tender offer for the remaining shares planned
- Cooperation Agreement concluded with Life Technologies

Regensburg, April 09, 2010 - The founders of GENEART AG Prof. Dr. Ralf Wagner,
Prof. Dr. Hans Wolf, Dr. Marcus Graf, and individual members of the management
as well as the venture capital companies EquiNet EarlyStage Capital and S-REFIT
AG, have signed contracts with Applied Biosystems Deutschland GmbH for selling
their GENEART shares. Applied Biosystems Deutschland GmbH thus holds about 58 %
of GENEART AG shares and is planning a voluntary public tender offer for the
remaining GENEART AG shares. Applied Biosystems Deutschland GmbH is the German
subsidiary of Life Technologies Corporation, a California/US biotechnology
company with 2009 revenues of 3.3B U.S. dollar and about 9,000 employees.
Furthermore, a cooperation agreement between GENEART AG and Life Technologies
has been concluded.

For further inquiries, please contact:

Dr. Karoline Stürmer
GENEART AG
Josef-Engert-Str. 11
93053 Regensburg
Germany
Phone: [phone]
Fax: [phone]
[e-mail]
www.geneart.com

Frank Ostermair
Better Orange IR & HV AG
Haidelweg 48
81241 Munich
Germany
Phone: [phone]
Fax: [phone]
[e-mail]
www.better-orange.de
Legal Information:

This document may contain estimates, prognoses and opinions about company plans
and objectives, products or services, future results, opinions about these
results or opinions leading up to these results. All these projections into the
future are subject to risk, uncertainty and unforeseeable change outside the
control of the GENEART Group. Many factors may lead to actual results, which
considerably deviate from the given projections for these results.

About GENEART AG:

In 2000 GENEART entered the Gene Synthesis market and has since become the
global market leader. Today, the company is one of the leading specialists in
the Synthetic Biology field. Experts at GENEART provide key technologies for the
development and production of new therapeutics and vaccines. Customers also take
advantage of GENEART services to customize enzyme attributes, such as the
attributes of enzymes used as detergent additives, and to construct bacteria,
which produce complex biopolymers or break down polymers, such as synthetics,
petroleum components, etc. GENEART´s service portfolio ranges from the
optimization and production of synthetic genes according to DIN EN ISO
9001:2008, to the generation of gene variants or complex gene libraries and the
production of cell lines, to the development and production of DNA and protein
based drug candidates. GENEART AG in Regensburg and its subsidiaries GENEART
Inc. in Toronto (Canada) and GENEART Inc. in San Francisco (USA) employ about
180 people. The company is listed on the German Stock Exchange since May 2006.
Since April 2010, the US-American Life Technologies Corporation, one of the
leading biotechnology companies worldwide with 2009 revenues of 3.3B U.S.
dollars and about 9,000 employees, is majority shareholder of GENEART AG.

About Life Technologies Corporation:

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools
company dedicated to improving the human condition. Our systems, consumables and
services enable researchers to accelerate scientific exploration, driving to
discoveries and developments that make life even better. Life Technologies
customers do their work across the biological spectrum, working to advance
personalized medicine, regenerative science, molecular diagnostics, agricultural
and environmental research, and 21st century forensics. Life Technologies had
sales of 3.3B U.S. dollar in 2009, employs approximately 9,000 people, has a
presence in approximately 160 countries, and possesses a rapidly growing
intellectual property estate of approximately 3,900 patents and exclusive
licenses. Life Technologies was created by the combination of Invitrogen
Corporation and Applied Biosystems Inc., and manufactures both in-vitro
diagnostic products and research use only-labeled products. For more information
on how we are making a difference, please visit our website:
http://www.lifetechnologies.com .

[HUG#1401654]

--- End of Message ---

Geneart AG
Josef-Engert-Str.11 Regensburg Germany

WKN: A0JJ4L;ISIN: DE000A0JJ4L4;

GENEART AG will become part of the US-Based Biotechnology Company Life Technologies Corp.: http://hugin.info/136633/R/1401654/356624.pdf

Wertpapiere des Artikels:
DE000A0JJ4L4